S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Prologis Stock Leading U.S. Logistics Boom
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:JYNT

Joint (JYNT) Stock Price, News & Analysis

$12.02
+0.02 (+0.17%)
(As of 04/17/2024 ET)
Today's Range
$11.86
$12.26
50-Day Range
$9.14
$13.09
52-Week Range
$7.31
$16.48
Volume
51,983 shs
Average Volume
54,212 shs
Market Capitalization
$177.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.50

Joint MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
78.9% Upside
$21.50 Price Target
Short Interest
Healthy
5.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Joint in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
284.62%
From $0.13 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.57 out of 5 stars

Medical Sector

434th out of 913 stocks

Patent Owners & Lessors Industry

4th out of 8 stocks

JYNT stock logo

About Joint Stock (NASDAQ:JYNT)

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

JYNT Stock Price History

JYNT Stock News Headlines

AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
The Joint Corp. (JYNT)
On Holding Posts Adj. Loss In Q4 - Quick Facts
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
Joint Q4 2023 Earnings Preview
Best joint personal loans of February 2024
The Joint Corp (JYNT)
The Joint Corp. Reports 2023 Operating Metrics
How to Get a Joint Personal Loan
See More Headlines
Receive JYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/17/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Patent owners & lessors
Sub-Industry
N/A
Current Symbol
NASDAQ:JYNT
Employees
444
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.50
High Stock Price Target
$30.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+78.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-9,750,000.00
Pretax Margin
1.39%

Debt

Sales & Book Value

Annual Sales
$117.70 million
Cash Flow
$0.73 per share
Book Value
$1.68 per share

Miscellaneous

Free Float
14,185,000
Market Cap
$177.66 million
Optionable
Optionable
Beta
1.59
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Peter D. Holt (Age 65)
    CEO, President & Director
    Comp: $469.55k
  • Jake  SingletonJake Singleton (Age 42)
    Chief Financial Officer
    Comp: $280.92k
  • Mr. Jorge Armenteros
    Senior Vice President of Operations
  • Mr. Charles Nelles
    Chief Technology Officer
  • Dr. Steven Knauf
    Vice President of Chiropractic & Compliance
  • Ms. Lori I. Abou Habib (Age 44)
    Chief Marketing Officer
  • Ms. Krischelle Tennessen
    Chief Human Resources Officer
  • Mr. Eric Simon
    Senior VP of Franchise Sales & Development
  • Mr. Craig P. Colmar J.D. (Age 71)
    Secretary
    Comp: $37k

JYNT Stock Analysis - Frequently Asked Questions

Should I buy or sell Joint stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Joint in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" JYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JYNT, but not buy additional shares or sell existing shares.
View JYNT analyst ratings
or view top-rated stocks.

What is Joint's stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Joint's shares. Their JYNT share price targets range from $13.00 to $30.00. On average, they predict the company's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 78.9% from the stock's current price.
View analysts price targets for JYNT
or view top-rated stocks among Wall Street analysts.

How have JYNT shares performed in 2024?

Joint's stock was trading at $9.61 on January 1st, 2024. Since then, JYNT shares have increased by 25.1% and is now trading at $12.02.
View the best growth stocks for 2024 here
.

When is Joint's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our JYNT earnings forecast
.

How were Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings data on Thursday, March, 7th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. The business earned $30.61 million during the quarter, compared to analyst estimates of $29.63 million. Joint had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 7.80%.

What is Peter D. Holt's approval rating as Joint's CEO?

87 employees have rated Joint Chief Executive Officer Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among the company's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Advanced Micro Devices (AMD), RTX (RTX), Salesforce (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did Joint IPO?

Joint (JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

Who are Joint's major shareholders?

Joint's stock is owned by many different institutional and retail investors. Top institutional investors include Bridge City Capital LLC (0.15%) and Avondale Wealth Management (0.13%). Insiders that own company stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel, Peter D Holt and Ronald V Davella.
View institutional ownership trends
.

How do I buy shares of Joint?

Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JYNT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners